COPENHAGEN, Denmark, Feb. 9, 2016 /PRNewswire/ -- Cardiac arrest leads to death in 9 out of 10 cases for the person affected. For medical doctor and CEO of Neurescue Habib Frost, this is an area ready for profound innovation.
When Habib participated in the Emergency Services during his training, he was shocked to experience how few survived: "A little girl just four months old, and a young woman in her 30s were some of the people I saw die. It was experiences that compelled me to approach cardiac arrest in a new way."
Cardiac arrest is the leading cause of death worldwide, and costs the lives of more than 1 million U.S. citizens annually, and between 350,000 - 700,000 lives annually in the EU. The cases are equally distributed between cardiac arrests inside hospitals and outside in everyday life.
The current treatment of cardiac arrest consists of chest compressions and defibrillation, despite the minority of patients being shockable when currently treated and thus able to respond to defibrillation.
The Neurescue™ device is a small, computer-controlled balloon catheter that is inserted into a blood vessel in the leg, the femoral artery, and occludes the aorta in order to redistribute the blood flow generated by chest compressions to the two most sensitive organs; the heart and brain.
"The increase in blood supply to the heart ensures that many more hearts can be resuscitated early. And if that fails, the increased blood supply to the brain protects against brain damage, allowing for more time to treat the underlying cause of the cardiac arrest. This approach can greatly improve the current low survival," said Habib Frost.
The effective combination of software, sensors and automation, known from e.g. Internet of Things, enables entirely new medical procedures, where Neurescue has developed a new procedure for cardiac arrest. 40% of people aged 25 - 74 years die prematurely as a result of heart disease, according to Medinfo.
"This includes people in the working age, children, young athletes and our parents. Not alone is this a market where there has not been significant progress in a long time. It is our obligation to do something about this," said Habib Frost.
Neurescue has applied for a broad IP portfolio, has developed and tested several prototypes and have proven the effectiveness of their product in a number of animal experiments, including cardiac arrest, civilian and military critical bleeding.
Habib Frost graduated as Denmark's youngest doctor at the age of 23, won Denmark's Best Idea in 2015 (Danske Ideer), and was awarded a scholarship for Singularity University at NASA Ames in Silicon Valley.
For a video of the procedure, visit: https://youtu.be/5Fu1IF9MJ-k
Neurescue is currently raising capital to bring the device into the hands of users.
In a round following seed funding, they are pursuing VC funding to develop a commercial version, and to pursue regulatory approval of the technology both inside hospitals and outside.
For a copy of the business plan and pitch deck, please contact through http://www.neurescue.com
011 45 53536760
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-tech-from-neurescue-can-save-those-suffering-from-leading-killer-of-us-citizens-300217181.html
SOURCE Neurescue Aps